Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: infusion of NMDA antagonist Clear all
Completed Phase 4 Interventional Results available

Ketamine Infusion for Adolescent Depression and Anxiety

NCT02579928
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

NCT03065335
View directory record Official record
Conditions
Healthy Volunteer, Major Depressive Disorder, Depression
Interventions
Ketamine, Placebo, Cobot TS MV robotic arm for TMS, NeurOptics PLRTM-30000 Pupillometer
Drug · Other · Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Suspended Phase 2 Interventional

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

NCT04912115
View directory record Official record
Conditions
Dyskinesias, Movement Disorders, Central Nervous System Diseases, Nervous System Diseases, Neurologic Manifestations
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
PharmaTher Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Chula Vista, California • Fountain Valley, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
D. Walter Wray
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional Results available

Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids

NCT00205712
View directory record Official record
Conditions
Psychoses, Substance-Induced
Interventions
Ketamine, Dexmedetomidine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

This is a Study to Determine the Antidepressant Effects of AZD6765

NCT00986479
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
AZD6765, Placebo to AZD6765
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)

NCT01100255
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Ketamine infusion, Saline
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Rapid Antidepressant Effects of Ketamine in Major Depression

NCT00088699
View directory record Official record
Conditions
Depression, Mood Disorders, Major Depresssion
Interventions
Ketamine, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 3 Interventional Results available

Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

NCT05233566
View directory record Official record
Conditions
Postoperative Depression
Interventions
Ketamine, Normal saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated Phase 1 Interventional

Pharmacokinetics of Low Dose Ketamine Infusion

NCT00618397
View directory record Official record
Conditions
Sedation, Opioid Tolerance
Interventions
Ketamine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine

NCT06788249
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Ketamine only
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 2 Interventional

Ketamine Alcohol (in Treatment-Resistant Depression)

NCT02122562
View directory record Official record
Conditions
Magnetic Resonance Imaging, Major Depression, Alcoholism
Interventions
Ketamine
Drug
Lead sponsor
Mark Niciu
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial

NCT02373124
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
infusion of NMDA antagonist
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence

NCT02437344
View directory record Official record
Conditions
Opioid Dependence
Interventions
CI-581aa, Naltrexone titration and XR-NTX initiation
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 28, 2026, 6:12 PM EDT
Completed No phase listed Observational

Neuromodulation to Facilitate the Effect of Ketamine

NCT01816958
View directory record Official record
Conditions
Depression, Chronic Pain, Substance Abuse
Interventions
co-administration of TMS and infused ketamine
Other
Lead sponsor
The Neuroscience Center, LLC
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Deerfield, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Not applicable Interventional Results available

Ketamine Infusion for Treatment-resistant Major Depressive Disorder

NCT01582945
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
N-acetylcysteine and ketamine, placebo and ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy

NCT03889756
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine infusion, Midazolam infusion
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Neurobiology of Suicide

NCT02543983
View directory record Official record
Conditions
Healthy Volunteers, Depression
Interventions
Magnetic Resonance Imaging scanner, 3T, NeurOptics PLRTM-3000 Pupillometer, Experimental Anxiety Devices, Magnetic Resonance Imaging scanner, 7T, Ketamine Hydrochloride
Device · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

NCT00690170
View directory record Official record
Conditions
Healthy Subjects
Interventions
Ketamine, Nicotine, Placebo, Ketamine and Nicotine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional Results available

Ketamine For Suicidal Ideation

NCT01507181
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 28, 2026, 6:12 PM EDT